[What has the GLAGOV clinical study shown?]
If we want to favorably influence the cardiovascular atherosclerotic disease, it is necessary to significantly lower LDL-C blood levels. PCSK9 inhibitors can significantly reduce LDL-cholesterol levels, being administered together with statins. However we focus on establishing whether this plays a role in influencing coronary atherosclerosis. The GLAGOV study is a multicentric, double-blinded and placebo-controlled study which during a 76-week period followed an impact of the treatment with evolocumab (PCSK9i) together with statin on the status of coronary atherosclerosis in patients with ischemic heart disease, and in comparison with the statin treatment. 968 patients at an average age of 60 have reached a significant decline in the levels of serum LDL-cholesterol (from 2.39 to 0.95 mmol/l) in the branch of the combined therapy, which led to a considerable reduction of percent atheroma volume in the coronary artery by 0.95% (in the branch of the statin-only therapy, the percent atheroma volume increased by 0.05%). The therapy was safe. As shown by the results, evolocumab can through additional reduction of blood levels of LDL-C favorably influence (reduce) coronary atherosclerosis.Key words: evolocumab - regression of coronary atherosclerosis - LDL-C blood levels.